In the latest act of the vaginal mesh litigation drama, plaintiffs' lawyers disputed J&J's claims that fishy phone calls recruiting women to file vaginal mesh-related suits are tainting the legal process and deserve further investigation.
A titanic struggle is nearing its end. Rivals Boston Scientific and Johnson & Johnson are done presenting their arguments in a legal spat involving the disastrous 2005-2006 bidding war and purchase of cardiology player Guidant. The purchase threatens to become an even worse decision for acquirer Boston Scientific, which would owe $7.2 billion if J&J gets its way.
One week after Johnson & Johnson said that women were being illegally solicited by unknown callers to sue over the company's transvaginal mesh devices, J&J has agreed to settle more than 100 product liability lawsuits regarding pelvic mesh products sold by its Mentor subsidiary.
Johnson & Johnson may have been third to bring its Ebola vaccine to human trials, but it is about to pick up the pace on developing its candidate, thanks to a €100 million grant from a European public-private partnership.
When it comes to currency, it's not been a good couple of weeks for multinational drugmakers. Switzerland's move to decouple the franc from the euro last week raised questions about the effects on Basel-based Roche and Novartis. And now, Johnson & Johnson's fourth-quarter results and 2015 forecast are triggering more foreign exchange worries.
Johnson & Johnson's antipsychotic med Invega Sustenna is already bringing in blockbuster-plus sales for J&J, and if the company has its way, a new, even longer acting formula will give the franchise an even bigger boost.
Johnson & Johnson was strongly hit by weaker currencies across Asia in the fourth quarter with the company struggling to hedge risk, indicating to executives that further impacts to the bottom line in these fast-growing markets are expected in 2015.
Johnson & Johnson has opened the doors on its Takeda-partnered biotech incubator in Israel, enrolling its first class of startups and advancing its global plan to accelerate R&D through external innovation.
Johnson & Johnson is working to make its medical device business grow as fast as the pharmaceutical side--but for now devices sales growth is slowing, while pharma is picking up fast.
Johnson & Johnson's new drugs came through again. Thanks to treatments from psoriasis-fighter Stelara to antipsychotic Invega Sustenna, the company's pharma sales were up a whopping 25% in the U.S. for 2014, and 15% worldwide, to $32.4 billion.